WillItSurvive
Pharma and healthcare groups · Switzerland

CRISPR Therapeutics

crisprtx.com ↗

Swiss biotech that makes CRISPR gene-editing therapies, co-owns the first FDA-approved one, CASGEVY.

Losing its protection
Assessed 24 July 2026 · Evidence as of 24 July 2026
The structural protection is eroding.
On the recordSince 24 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Zugo-cel and CTX310 clinical readouts, and Intellia's HAELO Phase 3 HAE data
The call

CRISPR Therapeutics has a real approved drug and cash to survive, but its next few years ride on trial data racing against Intellia and Beam, not on any AI disruption.

CRISPR Therapeutics uses a gene-editing tool called CRISPR to treat blood diseases and inherited conditions by fixing patients' cells. The company got the first FDA approval for this approach in late 2023, but only 64 patients have been treated so far and revenue is low, which is unusual for an approved drug. The real competition comes from Intellia Therapeutics (which is testing a version that works inside the body rather than outside it) and Beam Therapeutics (which uses a similar but potentially safer editing method), and both are moving fast. What matters most over the next year and a half is whether CRISPR's experimental treatments in development show they actually work in patients, whether Vertex (the partner selling the approved drug) can get more people to use it, and whether CRISPR can spend its cash pile wisely before it runs out.

Why
01
AI pressure: AI-driven protein/base-editor design labs (e.g. Profluent, big pharma AI discovery units). AI-designed editors could someday out-engineer CRISPR's tools, but no rival product is in clinics yet. Could AI do the core job? Unlikely.
02
Bigger players: Vertex Pharmaceuticals. Vertex co-owns and commercializes CASGEVY, taking the lion's share of economics while CRISPR remains the junior partner. Could a giant copy it? No, they are blocked.
03
What protects it. CASGEVY is a real, FDA-approved, revenue-generating product no peer has matched, plus $2.44B cash to fund the next readouts.
What would change this call
Intellia's HAELO Phase 3 HAE top-line data readout in mid-2026. Strong Intellia results would show in-vivo peers overtaking CRISPR's ex-vivo lead.
Zugo-cel autoimmune and B-cell lymphoma trial readouts in H2 2026. Clean data would show CRISPR diversifying beyond Vertex-dependent CASGEVY.
CASGEVY quarterly patient-infusion counts through 2026. Accelerating infusions would show commercial uptake overcoming logistical bottlenecks.
Key numbers
  • CASGEVY FY2025 revenue: $116 million (2026-02-12)
  • Cash and securities: $2.44 billion (2026-05-04)
  • Net loss Q1 2026: $122.9 million (2026-05-04)
Named risks
  • Quarterly cash burn of $120-130 million tied to binary H2 2026 clinical readouts. Severity: high
  • Flagship product CASGEVY revenue and economics shared with Vertex, limiting upside. Severity: high
  • Slow CASGEVY commercial ramp: only 64 patients infused in all of 2025. Severity: medium
  • Intellia and Beam advancing competing in-vivo and base-editing platforms on similar timelines. Severity: medium
  • Headcount decline since 2021-2022 peak may signal cost discipline pressure. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Intellia Therapeuticsgaining onPhase 3 in-vivo HAE/ATTR programs ahead of CRISPR's CTX310, HAELO data expected mid-2026
Beam TherapeuticscontestingBase-editing ex-vivo sickle cell program cited as potentially cleaner safety profile, 2026
Vertex PharmaceuticalscontestingCo-owns CASGEVY economics since 2015; CRISPR remains junior partner on flagship product
bluebird biogaining onCRISPR's CASGEVY reportedly outpacing bluebird's Lyfgenia after its safety warnings, 2026 (unconfirmed)
Questions people ask
Is CRISPR Therapeutics profitable in 2026?
No. CRISPR Therapeutics posted a net loss of $122.9 million in Q1 2026 and $130.6 million in Q4 2025, per its business update filings. The company runs on roughly $120-130 million quarterly burn against $2.44 billion cash as of March 31, 2026, not on product profit.
Who owns CASGEVY, CRISPR Therapeutics' flagship product?
CASGEVY is co-owned and commercialized by CRISPR Therapeutics and Vertex Pharmaceuticals under a collaboration dating to 2015. Vertex runs commercialization; CRISPR is the junior economic partner. As of Q1 2026, only $43 million in CASGEVY revenue was recorded that quarter, with CRISPR sharing that economics with Vertex.
Who is CRISPR Therapeutics' biggest competitor?
Intellia Therapeutics is the closest rival, running Phase 3 in-vivo CRISPR trials (lonvo-z for hereditary angioedema, with HAELO top-line data expected mid-2026) ahead of CRISPR's own in-vivo programs like CTX310. Beam Therapeutics also contests the space with a base-editing sickle cell program.
Could AI replace CRISPR Therapeutics' work?
AI tools like Stanford's CRISPR-GPT (Sept 2025) can speed guide-RNA design and target discovery, but cannot replace FDA-approved clinical data, physical cell-therapy manufacturing, or the December 2023 regulatory approval CRISPR holds for CASGEVY, the first approved CRISPR/Cas9 therapy.
How much cash does CRISPR Therapeutics have and how long will it last?
CRISPR Therapeutics held $2.44 billion in cash and marketable securities as of March 31, 2026, up from $1.98 billion at year-end 2025, boosted by a $550 million convertible notes raise in March 2026. Against a roughly $120-130 million quarterly net loss, that implies multi-year runway absent major spending changes.
Is CRISPR Therapeutics a takeover target?
As of April 27, 2026, one MarketBeat commentary floated CRISPR Therapeutics as a potential acquisition candidate amid a broader pharma patent-cliff narrative, but this is speculative analyst framing, not confirmed deal activity. No acquisition talks have been publicly announced as of mid-2026.
Timeline
  • 2026-05-04Q1 2026 results: CASGEVY revenue $43M, net loss $122.9M, cash $2.44B
  • 2026-03Raised $550 million via convertible notes, boosting cash reserves
  • 2026-02-12FY2025 results: CASGEVY revenue $116M, 64 patients infused in 2025
  • 2025-12-22Started Eli Lilly collaboration testing zugo-cel with pirtobrutinib for B-cell lymphoma
  • 2025-09Stanford releases CRISPR-GPT, an AI copilot for gene-editing experiment design
  • 2023-12CASGEVY becomes first FDA-approved CRISPR/Cas9 gene-edited therapy
  • 2016-10CRISPR Therapeutics IPO on Nasdaq
  • 2013Company founded by Emmanuelle Charpentier, Shaun Foy, Rodger Novak
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Community Health SystemsViatrisAccendra Health
More in Pharma and healthcare groups →
Sources